- Home
- XLO
as 12-23-2024 4:00pm EST
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers).
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | WALTHAM |
| Market Cap: | 42.1M | IPO Year: | 2021 |
| Target Price: | $4.00 | AVG Volume (30 days): | 738.6K |
| Analyst Decision: | Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.42 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.50 - $1.93 | Next Earning Date: | 11-07-2024 |
| Revenue: | $4,620,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 368.76% |
Stock Insider Trading Activity of Xilio Therapeutics Inc. (XLO)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| GILEAD SCIENCES, INC. | XLO | 10% Owner | Dec 18 '24 | Buy | $1.04 | 1,759,978 | $1,830,377.12 | 9,105,451 |
Latest Xilio Therapeutics Inc. News
XLO Breaking Stock News: Dive into XLO Ticker-Specific Updates for Smart Investing
GlobeNewswire
4 days ago
Xilio Therapeutics to Present Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer at ASCO GI
GlobeNewswire
7 days ago
Xilio Therapeutics Appoints Caroline Hensley as Chief Legal Officer
Zacks
14 days ago
After Golden Cross, Xilio Therapeutics, Inc. (XLO)'s Technical Outlook is Bright
Simply Wall St.
17 days ago
Here's Why We're Not Too Worried About Xilio Therapeutics' (NASDAQ:XLO) Cash Burn Situation
GlobeNewswire
20 days ago
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
2 months ago
Xilio Therapeutics Announces Initial Clinical Trial Data from Phase 1C Dose Escalation for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Advanced Solid Tumors
GlobeNewswire
2 months ago
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2024 Financial Results
GlobeNewswire
2 months ago
Xilio Therapeutics to Present Initial Phase 1C Dose Escalation Data for XTX101 (Vilastobart) in Combination with Atezolizumab in a Late-Breaker Poster at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
Compare XLO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "XLO Xilio Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.